The company also shared more details of its exit from the TAVR market and the impact of FDA layoffs on product review times.

Boston Scientific leads in MedSurg and Cardiovascular with strong Q1 growth, solid margins, and smart acquisitions. Find out ...

Edwards Lifesciences (EW) stock and Medtronic (MDT) stock gain as Boston Scientific (BSX) halts sales of ACURATE heart valves ...

Boston Scientific Corp. closed 0.93% short of its 52-week high of $107.17, which the company achieved on February 5th.

Camille Chang Gilmore, Boston Scientific’s global chief DEI officer announced she is leaving the company after two decades of ...

Boston Scientific ends global sales of ACURATE valves and halts FDA pursuit, citing rising regulatory burdens; expects to ...

Boston Scientific is pulling its latest transcatheter aortic heart valve platform from the worldwide market and said it will ...

Boston Scientific (NYSE:BSX) shares fell 4% after the company announced it will discontinue global sales of its ACURATE neo2 ...

Boston Scientific said it would halt worldwide sales of its Acurate devices due to “increased clinical and regulatory ...

Boston Scientific said on Wednesday it will stop pursuing U.S. approval for its experimental heart device due to increased clinical and regulatory requirements.

Boston Scientific said it still expects to achieve its second-quarter and full-year 2025 sales and adjusted per-share earnings guidance despite the anticipated financial impacts from the ...

Boston Scientific has a better P/E ratio of 76.28 than the aggregate P/E ratio of 53.33 of the Health Care Equipment & Supplies industry. Ideally, one might believe that Boston Scientific Inc. might ...